Opinion/decision on a Paediatric investigation plan (PIP): Nuvaxovid, SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda, decision type: PM: decision on the application for modification of an agreed PIP, ther

Opinion/decision on a Paediatric investigation plan (PIP): Nuvaxovid, SARS-CoV-2, spike protein, recombinant, expressed in Sf9 cells derived from Spodoptera frugiperda, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Infections and infestations, PIP number: EMA/PE/0000234339